Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion : a review. / Kårhus, Martin L; Brønden, Andreas; Sonne, David P; Lauritsen, Tina Vilsbøll; Knop, Filip Krag.

I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 9, 09.2017, s. 1214-1222.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Kårhus, ML, Brønden, A, Sonne, DP, Lauritsen, TV & Knop, FK 2017, 'Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review', Diabetes, Obesity and Metabolism, bind 19, nr. 9, s. 1214-1222. https://doi.org/10.1111/dom.12946

APA

Kårhus, M. L., Brønden, A., Sonne, D. P., Lauritsen, T. V., & Knop, F. K. (2017). Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review. Diabetes, Obesity and Metabolism, 19(9), 1214-1222. https://doi.org/10.1111/dom.12946

Vancouver

Kårhus ML, Brønden A, Sonne DP, Lauritsen TV, Knop FK. Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review. Diabetes, Obesity and Metabolism. 2017 sep.;19(9):1214-1222. https://doi.org/10.1111/dom.12946

Author

Kårhus, Martin L ; Brønden, Andreas ; Sonne, David P ; Lauritsen, Tina Vilsbøll ; Knop, Filip Krag. / Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion : a review. I: Diabetes, Obesity and Metabolism. 2017 ; Bind 19, Nr. 9. s. 1214-1222.

Bibtex

@article{e672dcbe025a45bfaf726abb8b0c91ae,
title = "Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review",
abstract = "Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G protein-coupled receptor 5 (TGR5) and the nuclear farnesoid X receptor (FXR), in intestinal L cell. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.",
keywords = "Journal Article, Review",
author = "K{\aa}rhus, {Martin L} and Andreas Br{\o}nden and Sonne, {David P} and Lauritsen, {Tina Vilsb{\o}ll} and Knop, {Filip Krag}",
note = "This article is protected by copyright. All rights reserved.",
year = "2017",
month = sep,
doi = "10.1111/dom.12946",
language = "English",
volume = "19",
pages = "1214--1222",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion

T2 - a review

AU - Kårhus, Martin L

AU - Brønden, Andreas

AU - Sonne, David P

AU - Lauritsen, Tina Vilsbøll

AU - Knop, Filip Krag

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G protein-coupled receptor 5 (TGR5) and the nuclear farnesoid X receptor (FXR), in intestinal L cell. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.

AB - Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G protein-coupled receptor 5 (TGR5) and the nuclear farnesoid X receptor (FXR), in intestinal L cell. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.

KW - Journal Article

KW - Review

U2 - 10.1111/dom.12946

DO - 10.1111/dom.12946

M3 - Review

C2 - 28304141

VL - 19

SP - 1214

EP - 1222

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -

ID: 174428571